FENC Fennec Earnings per share for the last twelve months

FENC (Fennec Pharma) - company brandmark

Fennec Pharmaceuticals (FENC) has created a unique protective environment for patient hearing by integrating Pedmark into pediatric therapy protocols. The rolling specific profit metric visualizes the market response, where the current level is -0.13. Growth is driven by the expansion of insurance coverage in the US and expansion into Europe, while its status as a niche monopolist guarantees a stable cash flow and operational resilience.

FENC (Fennec Pharmaceuticals) Net earnings per share for the last 12 months history from 07/04/2022 to 11/12/2026

Fennec Pharma - analytical breakdowns and key metrics (FENC)

- current quotes and average value forecast:
Price Chart Fennec Pharmaceuticals|FENC - Average Forecast Price
- market capitalization data:
Market Value Fennec Pharmaceuticals Inc.|FENC - Business Value
- shareholders' equity book value data:
Book Value per Share Fennec Pharmaceuticals|FENC - Company Net Assets|Market Value to Book Value Ratio fennecpharma.com|FENC - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Fennec Pharmaceuticals|FENC - Long-Term Debt to Equity|Short-Term Debt to Equity Fennec Pharmaceuticals Inc|FENC - Company Cumulative Debt|Debts to Book Capitalization Fennec Pharmaceuticals Inc.|FENC - Long-Term Indebtedness|Company Current Liabilities Fennec Pharmaceuticals|Quick Liquidity Indicator fennecpharma.com
- net income and valuation multiples indicators:
FENC - Final Profit|Future Profit Fennec Pharmaceuticals|FENC - Market Price to Net Income Ratio|Forward P/E Multiple Fennec Pharmaceuticals Inc.|FENC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Fennec Pharmaceuticals Inc.|FENC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Fennec Pharmaceuticals|FENC - Earnings per share for the trailing year|Quarterly EPS earnings growth fennecpharma.com|FENC - Earnings growth in current year|Net earnings per share growth forecast for next year Fennec Pharmaceuticals
Basic company analysis:Fennec Pharmaceuticals (FENC)
Mass-produced product of Fennec Pharmaceuticals Inc

The efficiency of express delivery for oncology drugs to hospitals directly impacts the operational resilience of Fennec Pharmaceuticals (FENC). By analyzing the current annual net income per share, an investor can observe the 12-month earnings per share adjusted for the impact of share issuance, which allows them to filter out market noise and assess the business's real growth trajectory and its fundamental defensive qualities.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis Pharma NVCT|Coherus - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Cardiff Oncology, Inc.|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharma CTXR|Net earnings per share for the last 12 months CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months